Supplementary Table 1. **Overview of platelet counts (all-subjects population)**

	Placebo	**GSK2330811**				
		0.1 mg kg^{-1}	**0.3 mg kg^{-1}**	**1 mg kg^{-1}**	**3 mg kg^{-1}**	**6 mg kg^{-1}**
	N=10	**N=6**	**N=6**	**N=6**	**N=6**	**N=6**
Maximum CTCAE grade, n (%)						
Grade 1 (75–150 GI L^{-1})	0 (0)	0 (0)	1 (17)	2 (33)	5 (83)	5 (83)
Grade 2 (50–<75 GI L^{-1})	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (17)
Nadir, mean, (95% CI)	203.3 (181.2, 225.4)	191.2 (165.8, 216.5)	188.5 (147.0, 230.0)	159.2 (128.6, 189.8)	145.0 (107.1, 182.9)	108.3 (84.1, 132.5)
% change from baseline of nadir, mean (95% CI)	-9.3 (-14.0, -4.7)	-7.6 (-12.2, -2.9)	-8.5 (-20.5, 3.5)	-24.8 (-31.2, -18.4)	-39.7 (-46.0, -33.4)	-54.6 (-65.0, -44.3)
Median days to nadir (min, max)[a]	41.0 (2, 83)	9.0 (1, 83)	23.5 (9, 55)	20.0 (13, 26)	26.0 (13, 27)	20.0 (17, 28)

[a]Days to platelet count nadir calculated as study day of nadir – 1

CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events; GI L^{-1}, 10^9 cells/litre